Blueprint Medicines (BPMC) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

External links

Employees

Data from SEC filings

Employee count

CEO pay ratio

CEO Salary

Median Employee Salary

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Climate Energy Efficiency Environment Environmental Environmental Protection Intensity LEED Lifecycle Materials Natural Resources Nature Offset Package Packaging Pandemic Raw Materials Renewable Toxic Waste Watershed Access Access and affordability African American Asian Attrition Benefits Black California Consumer Privacy Act Citizenship Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Data Security Death Demographic Disability Diversity Diversity and Inclusion Drug Pricing Employee Employee Engagement Employee Retention Engagement Ethnic Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Minority Pay for Performance Perquisites Privacy Product Quality Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skill Skilled Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Action Plan Antitrust Assessment Assurance Attorney General Attorneys General Audit Board Refreshment Bonus Chronic Classified Classified Board Clawback Commitment Conflict of Interest Corporate Governance Corporate Purpose Department of ESG Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Mission Other Public Company Boards Oversee Oversight Perquisite Plaintiff Pledging Proxy Access Purpose Quality Standard R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Self-evaluation Stewardship Stockholder Outreach Strategy Sustainability Sustainable Targets Tax Tenure Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The Company held its Annual Meeting of Stockholders on June 21, 2022 (the “Annual Meeting”). The following is a summary of the matters voted on at that meeting.

The Company’s stockholders elected Jeffrey W. Albers, Mark Goldberg, M.D. and Nicholas Lydon, Ph.D. as Class I directors, each to serve for a three-year term expiring at the 2025 annual meeting of stockholders and until his successor has been duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows:

Name	Votes For	Votes Withheld	Broker Non- Votes
Jeffrey W. Albers	38,338,820	15,880,558	1,984,429
Mark Goldberg, M.D.	21,917,758	32,301,620	1,984,429
Nicholas Lydon, Ph.D.	32,673,870	21,545,508	1,984,429

The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders’ non-binding, advisory vote with respect to compensation paid to the Company’s named executive officers were as follows:

Votes For		Votes Against		Votes Abstaining		Broker Non-Votes
53,277,135		916,091		26,152		1,984,429

The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting for the fiscal year ending December 31, 2022. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes For		Votes Against		Votes Abstaining
55,836,831		343,817		23,159